| Study |
Design |
Location |
Population |
Intervention arms |
RR (95% CI) |
ARR |
| iPrEx |
Phase III, safety and efficacy |
Brazil, Ecuador, Peru, South Africa, Thailand, United States |
2499 MSM |
Daily oral TDF-FTC |
44% (15,63) |
2.2% |
| TDF2 |
Phase III, safety and efficacy |
Botswana |
1219 heterosexual men and women |
Daily oral TDF-FTC |
75% (55,87) |
2.5% |
| Partners rEP |
Phase III, safety and efficacy |
Kenya, Uganda |
4758 serodiscordant heterosexual couples |
Daily oral TDF;
Daily oral TDF-FTC |
62% (22,83) |
2.4% |
| FEM-PrEP |
Phase III, safety and effectiveness |
Kenya, Tanzania, South Africa |
2120 heterosexual women |
Daily oral TDF |
6% (-52,41) |
0.2% |
RR: Relative Risk; ARR: Absolute Risk Reduction; MSM: Men Who have Sex with Men; TDF-FTC: Tenofovir-Emtricitabine; TDF: Tenofovir disoproxil fumarate |
